Pankti Reid

Also affiliated with PharmacoGenetics (China)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19”.

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

medRxiv(2020)10.1101/2020.07.20.20157503

N/A

0DataRank · unranked

26 citations

Brian L. Heiss, Sherin J. Rouhani, Jonathan Trujillo, Jovian Yu, Alec Kacew +18 more

Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis

Clinical and Experimental Rheumatology(2021)10.55563/clinexprheumatol/e3hfts

N/A

0DataRank · unranked

3 citations

Keith Danahey, Marco Lopez Velazquez, Mark J. Ratain, Peter H. O’Donnell, Pankti Reid

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps2676

N/A

0DataRank · unranked

29 citations

Michael Dougan, Sarthak Gupta, Laura C. Cappelli, Tamiko R. Katsumoto, Osama E. Rahma +15 more

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Expert Review of Clinical Immunology(2023)10.1080/1744666x.2023.2249237

N/A

0DataRank · unranked

28 citations

Pankti Reid, Victor Yang, David Liew, Alexander C. Peterson, Aaron Baraff +3 more

Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis

Respiratory Medicine(2023)10.1016/j.rmed.2023.107330

N/A

0DataRank · unranked

9 citations

Renea Jablonski, Mary E. Strek, Christine M. Bestvina, Mei‐Yin C. Polley, Pankti Reid +1 more

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

OncoImmunology(2023)10.1080/2162402x.2023.2261264

N/A

0DataRank · unranked

8 citations

Sabina Sandigursky, Juhee Song, María A. López-Olivo, Houssein Safa, Samuel Cytryn +12 more

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.46336

N/A

0DataRank · unranked

14 citations

Laura S. Gold, Maureen Dubreuil, James S. Andrews, Pankti Reid, David Liew +10 more

Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study

Cancers(2024)10.3390/cancers16101892

N/A

0DataRank · unranked

5 citations

Jacobi Hines, Rachel Baccile, Sherin J. Rouhani, Pankti Reid, Sharjeel Syed

Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis

Lara D. Veeken(2025)10.1093/rheumatology/keaf096

N/A

0DataRank · unranked

8 citations

Laura S. Gold, Maureen Dubreuil, James S. Andrews, Pankti Reid, David Liew +8 more